Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Simufilam

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
    Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates

    08 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/08/2926904/8339/en/Cassava-Sciences-Reports-Q2-2024-Financial-Results-and-Operational-Updates.html

    GLOBENEWSWIRE
    08 Aug 2024
    Share Share
    Cassava Sciences Announces Expansion of Open-Label Extension Trials
    Cassava Sciences Announces Expansion of Open-Label Extension Trials

    30 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/30/2920979/8339/en/Cassava-Sciences-Announces-Expansion-of-Open-Label-Extension-Trials.html

    GLOBENEWSWIRE
    30 Jul 2024
    Share Share
    Cassava Sciences Issues Statement on Former Science Advisor
    Cassava Sciences Issues Statement on Former Science Advisor

    28 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/28/2906117/8339/en/Cassava-Sciences-Issues-Statement-on-Former-Science-Advisor.html

    GLOBENEWSWIRE
    28 Jun 2024
    Share Share
    Cassava Sciences Q1 2024 Financials, Simufilam Phase 3 Updates
    Cassava Sciences Q1 2024 Financials, Simufilam Phase 3 Updates

    10 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/10/2879821/8339/en/Cassava-Sciences-Reports-Q1-2024-Financial-Results-and-Clinical-Updates-on-Phase-3-Trials-of-Simufilam.html

    GLOBENEWSWIRE
    10 May 2024
    Share Share
    Cassava Announces Completion of Safety Review of Oral Simufilam Pha 3 Trials
    Cassava Announces Completion of Safety Review of Oral Simufilam Pha 3 Trials

    25 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/25/2851698/8339/en/Cassava-Sciences-Announces-Completion-of-an-Interim-Safety-Review-of-Oral-Simufilam-On-going-Phase-3-Trials.html

    GLOBENEWSWIRE
    25 Mar 2024
    Share Share
    Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam
    Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam

    06 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/06/2774211/8339/en/Cassava-Sciences-Completes-Enrollment-for-Pivotal-Phase-3-Program-of-Simufilam-in-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    06 Nov 2023
    Share Share